In this video we take a closer look at the Australian medical cannabis market. With over 100,000 prescribed medical cannabis patients annually receiving access via SAS-B (Special Access Scheme) or Authorised prescribers scheme it is certainly a market of interest.

Australia’s medical patient base also includes CBD containing products as part of the prescription numbers. Toward the end of last year CBD products found a rescheduling to schedule 3 however these products still need to go through standard approval as medicines and get ARTG listed.

Australia has over 45 licensed medical cultivation facilities and also has cannabis research licenses. With several cannabis companies listed on the ASX – Australian Securities Exchange we have some reasonable visibility on activities in the market.

The fact that Australia has approved over 30,000 patient approvals from January – March 2022 is also encouraging.

Sibusiso Xaba provides us with better insight into the Australian market following a recent visit to the region.

Host: Jeff Verlinden
Mobile: +27 63 291 3334/Local 063 291 3334
Email: jeff@separations.co.za

Guest Speaker: Sibusiso Xaba
African Cannabis Advisory Group
Email: media@aca-g.com

Keywords in the interview: cannabis entrepreneurship, cannabis investment banking, cannabis networking, medicinal cannabis, botanical medicine, global cannabis, international cannabis, cannabis licensed providers, special access schemes, , dossiers, imports, exports, cannabis headlines, Marketing Authorization, access to unregistered cannabis medicine, cannabis testing, monograph, pharmaceutical businesses, quality control, hemp, marijuana, dagga, TGA, Therapeutic Goods Association, TGO-93, TGO-100.

source